SCHEMBL15865508

SCHEMBL15865508

[O]C1CCC2CCCN1C2

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.35
ALDH1A1 P00352 1/20 0.32
MAN2B1 O00754 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8637745 0.85
SCHEMBL701424 0.71 SLC18A3 (0.35) SLC18A3ALDH1A1MAN2B1
SCHEMBL3278742 0.71 SLC18A3 (0.45) SLC18A3ALDH1A1MAN2B1
SCHEMBL11086482 0.64 SLC18A3 (0.38) SLC18A3ALDH1A1
SCHEMBL27729 0.62
SCHEMBL11350359 0.62
SCHEMBL15265282 0.61 ALDH1A1 (0.42) ALDH1A1
SCHEMBL16570976 0.60
SCHEMBL3429838 0.60
SCHEMBL875158 0.60 CHRNA7 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991980-B1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-01-02 EP disclosed
US-9790212-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-10-17 US disclosed
EP-3019494-B1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) 2017-06-21 EP disclosed
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-02-02 US disclosed
US-9556157-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-01-31 US disclosed
US-9505745-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-11-29 US disclosed
US-9382234-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2016-07-05 US disclosed
US-20160130261-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-12 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2015-10-29 US disclosed
EP-2931707-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline LLC (US) 2015-10-21 EP disclosed
WO-2014107277-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307480-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 SLC18A3 4846/4885ALDH1A1 2517/4885MAN2B1 3187/4885
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 SLC18A3 4846/4885ALDH1A1 2517/4885MAN2B1 3187/4885
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 SLC18A3 4846/4885ALDH1A1 2517/4885MAN2B1 3187/4885
US-20160130261-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 SLC18A3 4846/4885ALDH1A1 2517/4885MAN2B1 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.